Printer Friendly

ALAMAR BIOSCIENCES ANNOUNCES MAJOR INTERNATIONAL ALLIANCE; AGREEMENT EXPANDS WORLDWIDE MARKETS AND R&D OPPORTUNITIES

 SACRAMENTO, Calif., Nov. 22 /PRNewswire/ -- Alamar Biosciences, Inc. (NASDAQ: ALMR) announced today that it has signed a letter of intent to collaborate with Sclavo Diagnostics, Srl of Milan, Italy, a major manufacturer and distributor of microbiology and clinical chemistry products to distribute Alamar biomedical products through large portions of Europe. The letter of intent also calls for the joint development of future products, joint distribution rights, manufacturing rights and a Sclavo investment in Alamar.
 Sclavo will distribute Alamar identification and susceptibility products in most of Europe, while Alamar expects to distribute the Sclavo immunoassay products in the United States. The two companies also expect to collaborate on the development of products in infectious disease diagnostics.
 Kenneth D. Miller, chief executive officer of Alamar said, "The alliance elevates Alamar to a new level. Now our products truly will have access to European markets and our research and development capability will be significantly enhanced. Sclavo has a successful history as a manufacturer and distributor in Europe and we expect Sclavo will have a material impact on our revenues in 1994. We look forward to the collaboration evolving into a long and productive relationship as we jointly address the microbiology market." Sclavo has manufactured and distributed microbiology products for over two decades.
 Under the terms of the letter, Alamar products will be distributed in Italy, Germany, Switzerland, Austria, Netherlands, Belgium, Luxembourg, Turkey and Greece. Sclavo has agreed to sever its distribution agreement with a competing product line from the MicroScan division of Baxter International which Sclavo successfully introduced in Italy in 1989. Sclavo will announce the Alamar product distribution at Italy's premier laboratory convention in Milan, starting November 23.
 Luigi Pirovano, Sclavo's chief executive officer said, "Our analysis revealed that Alamar has the best technology to capture significant growth in
the markets we serve in Europe. We are pleased to be associated with Alamar and are impressed with their R&D and marketing capabilities. The collaboration agreement will provide Sclavo with greater opportunities for development of new products through joint R&D and access to the U.S. market via Alamar's sales and marketing organization."
 As a commitment to the alliance, Sclavo will also purchase an approximate 4-5 percent interest in Alamar. The terms and conditions of the investment element of the relationship were not revealed.
 Consummation of the proposed alliance is subject to the execution of definitive agreements, which the parties expect to accomplish shortly.
 Alamar currently distributes its identification and susceptibility products through distributors in France, Spain, Mexico, Puerto Rico and South America. The Scalvo distribution agreement will not interfere with these existing agreements. The company has a direct sales force in the U.S. that sells to hospitals and reference laboratories.
 Common stock in Alamar Biosciences, Inc. is traded on NASDAQ under the symbol ALMR. The company develops, manufactures and markets in vitro (outside the body) testing products for hospitals, reference laboratories and other health care providers. Alamar also markets alamarBlue(TM), an indicator dye for determining cell viability in research and biotechnology applications.
 For information on Alamar Biosciences, Inc. by fax, dial 1-800-PRO-INFO, extension 141.
 -0- 11/22/93
 /CONTACT: Kenneth D. Miller or Mark L. Santor, both of Alamar Biosciences, 916-567-3475, or Elizabeth Truax (media) or Lillian Armstrong (investors), 415-986-1591, both of Financial Relations Board/
 (ALMR)


CO: Alamar Biosciences, Inc.; Sclavo Diagnostics Srl ST: California IN: MTC SU:

TM -- NY008 -- 6695 11/22/93 09:06 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Nov 22, 1993
Words:569
Previous Article:/C O R R E C T I O N -- MASSACHUSETTS ELECTRIC/
Next Article:COMPANY SUBMITS 510(k) APPLICATION TO FDA FOR PHENCYCLIDINE ASSAY
Topics:

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters